**Supplementary Table 3.** Inclusion and exclusion criteria for cohort 2d (advanced HER2-expressing non-breast/non-gastric or HER2-mutant solid tumors)

|  |  |
| --- | --- |
| **Inclusion criteria** | **Exclusion criteria** |
| * Measurable disease based on RECIST version 1.1 * Able to provide fresh tumor biopsy samples * At least 1 of the following: * Non-breast/non-gastric, or GEJ adenocarcinoma pathologically documented HER2-expressing (determined by IHC, FISH, Next Generation Sequencing or other method) solid tumor that is refractory to standard treatment or for which no standard treatment is available * HER2 mutation in a pathologically documented advanced unresectable or metastatic solid tumor of any type that is refractory or for which no standard treatment is available | * Multiple primary malignancies within 3 years * Excludes contralateral breast cancer, adequately resected nonmelanoma skin cancer, and in situ disease that has been curatively treated |

FISH, fluorescence in situ hybridization; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; RECIST, Response Evaluation Criteria in Solid Tumors.